No specifications available.
DORZOD
First U.S. FDA Approved Topical Carbonic Anhydrase Inhibitor
Clinically proven topical carbonic anhydrase inhibitor for effective IOP reduction.
Reduces Aqueous Humor Secretion
Inhibits carbonic anhydrase to lower intraocular pressure effectively.
Protects Optic Nerve Head
Accelerates blood velocity, provides vasoprotection and effectively treats glaucoma & ocular hypertension.
Glaucoma
Hypertension
Intraocular Pressure
Reduction